Fapon Biotech Unveils Ultra-High-Speed Chemiluminescence Immunoassay System Shine i8000/9000 at CACLP 2023, Reinforcing Innovation-Driven Strategy

On May 28, 2023, the 20th China Association of Clinical Laboratory Practice (CACLP) Expo for Laboratory Medicine and Transfusion Instruments & Reagents grandly opened at the Nanchang Greenland International Expo Center. This year, FAPON BIOTECH showcased its single-unit detection speed reaching up to900 tests/hour's Blockbuster New ProductShine i8000/9000 Fully Automated Chemiluminescence Immunoassay SystemMaking a dazzling debut, FAPON BIOTECH comprehensively showcased its significant progress and achievements in the open-platform ecosystem model and raw material business by sharing its latest strategies for the chemiluminescence ecosystem, as well as key products offering core raw materials and reagent solutions for in vitro diagnostics.

On the morning of the 28th, at the new product launch event for the ultra-high-speed fully automated chemiluminescence immunoassay system themed “Beyond Speed, Precision Perfected,” FAPON BIOTECH and its online and offline audiences jointly witnessedOfficial Launch of the Shine i8000/9000 Fully Automated Chemiluminescence Immunoassay System.

FAPON BIOTECH’s Shine i8000/9000 is positioned as a high-efficiency, intelligent solution tailored for medium-to-large clinical laboratories. Its primary application scenarios include laboratory centers of large medical institutions, third-party clinical testing laboratories, large-scale health examination centers, group testing centers in the livestock industry, and animal disease prevention and control centers, thereby meeting the urgent demand of medical laboratories for high-throughput diagnostic instruments.

The Shine i8000/9000 features high efficiency and precision, intelligent convenience, flexibility and openness, as well as stability and reliability. With a single-unit throughput of up to 900 tests per hour and a linked-system throughput of up to 3,600 tests per hour (using four units), the first results are available within 10 minutes, maximizing laboratory workflow efficiency. Additionally, the Shine i8000/9000 employs industry-advanced, highly polished sampling probes, enabling a minimum sample volume as low as 5 μL. The coefficient of variation (CV) for pipetting accuracy is ≤2%, and the overall system CV is ≤3%, demonstrating exceptional precision. Furthermore, the Shine i8000/9000 has undergone comprehensive upgrades in both exterior design and internal functionality, delivering a more user-friendly and intelligent interactive experience.

To collaborate with industry partners in building an open and inclusive ecosystem, the Shine i8000/9000 fully supports multiple chemiluminescence immunoassay platforms, including AE, AP, HRP, and ABEI, and is compatible with all consumables from the Shine product series. Furthermore, the Shine i8000/9000 features abundant interfaces, enabling networked expansion of 1 to 4 units and supporting connectivity with laboratory automation lines and other instruments. This expandability significantly reduces sample turnaround time and enhances laboratory operational efficiency.

Since FAPON BIOTECH pioneered the open platform ecosystem strategy, its chemiluminescence platform ecosystem has made positive progress in multiple aspects. To date, FAPON BIOTECH hasWith over 250 ecosystem partners, FAPON BIOTECH’s fully automated chemiluminescence immunoassay systems achieved shipments of more than 3,000 units within just three years of launch.Has earned the recognition of a broad base of customer partners.

At the satellite symposium held on the afternoon of the 28th, Hu Jiangwei, Vice President of FAPON BIOTECH, shared the company’s latest strategic development plans for its chemiluminescence ecosystem. To further leverage the advantages of its open IVD platform and collaborative ecosystem model, FAPON BIOTECH will continue to integrate its resources in technology, industry, and distribution channels. The company aims to provide partners with diverse collaboration models, including high-quality raw materials, reagent development, innovative instruments, technology transfer, and comprehensive solutions. FAPON BIOTECH seeks to join forces with more partners across the IVD industry chain to foster an open and synergistic environment, thereby promoting the prosperous development of the IVD sector.

At this exhibition, FAPON BIOTECH showcased its key raw material products in the series of infectious diseases, thyroid function, and sex hormones, with a special focus on the latest R&D achievements in respiratory influenza, cardiac markers, and blockers.

FAPON BIOTECH is dedicated to building a premium portfolio of influenza raw materials. It conducts inclusivity testing on over 60 influenza subtypes/strains worldwide, performs cross-reactivity and interference studies on substances specified in regulatory review guidelines, and simultaneously benchmarks its products against kits from leading domestic and international manufacturers to ensure the superior performance of its antibody raw materials. Furthermore, FAPON BIOTECH provides tailored raw material recommendations to meet the diverse design requirements of its customers and partners, while guaranteeing stable supply to enable worry-free production for reagent manufacturers.

Within the cardiac marker portfolio, sST2 is a new addition to FAPON BIOTECH’s family of cardiac biomarkers. Available in diverse formats—including antibodies, antigen raw materials, and chemiluminescence reagent solutions—the product line delivers superior performance, providing robust support for reagent manufacturers in developing high-quality sST2 assays.

Meanwhile, FAPON BIOTECH has launched a range of high-performance blocking agents that are widely used across multiple IVD testing platforms. These products are suitable for the majority of in vitro diagnostic applications, including tumor markers, cardiac markers, and infectious diseases. They deliver excellent blocking performance, offering high quality at competitive prices, stable supply, and comprehensive support, thereby fully safeguarding the accuracy of immunoassays.

On the “fast track” of rapid development in the in vitro diagnostics (IVD) industry, FAPON BIOTECH will continue to deepen its foundational raw material technology platforms, striving to provide global IVD customers and partners with high-performance core raw materials for IVD reagents, reagent solutions, and open instrument platforms. By continuously integrating its resources and advantages and increasing investment in its open-platform ecosystem strategy, FAPON BIOTECH aims to empower more IVD partners, so that advances in diagnostic technology can benefit more people and contribute to human health.

The excitement at this year’s CACLP continues! You are welcome to visit FAPON BIOTECH at Booth A3-2013 and join us in unlocking new possibilities for the development of the in vitro diagnostics industry!